Safety & Antiviral Activity of Remdesivir for severe COVID-19 (Gilead 5773)
The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to the normalization of temperature and oxygen saturation through Day 14 in participants with severe coronavirus disease (COVID-19).
| Imperial PI | Professor Sarah Fidler |
| Trial Sponsor | Gilead Sciences Inc. |
| Study type | Interventional |
| Study status | Closed to recruitment |
Find out more about this study here.
ClinicalTrials.Gov record
Safety & Antiviral Activity of Remdesivir for moderate COVID-19 (Gilead 5774)
The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to the time to discharge in participants with moderate coronavirus disease (COVID-19).
| Imperial PI | Professor Graham Cooke |
| Trial Sponsor | Gilead Sciences Inc. |
| Study type | Interventional |
| Study status | Closed to recruitment |
Find out more about this study here.
ClinicalTrials.Gov record